News >

Olaparib/Durvalumab Combo Effective for BRCA-mutant Breast Cancer

Silas Inman @silasinman
Published: Thursday, Dec 14, 2017

Susan M. Domchek, MD
Susan M. Domchek, MD
The combination of olaparib (Lynparza) and durvalumab (Imfinzi) demonstrated a disease control rate (DCR) of 80% for pretreated patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer, according to phase II findings from the MEDIOLA trial presented at the 2017 San Antonio Breast Cancer Symposium.1

The phase II DORA trial is planned to further assess the combination of olaparib and durvalumab for patients with platinum-treated triple-negative breast cancer. This trial plans to enroll 60 participants with a primary endpoint of PFS. The estimated primary completion date for the trial is October 2019 (NCT03167619).

References

  1. Domchek SM, Postel-Vinay S, Bang Y-J, et al. An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC). Presented at: the 2017 San Antonio Breast Cancer Symposium; Dec. 5-9, 2017. Abstract PD6-11.
  2. Robson M, Im S-A, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377:523-533.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x